This paper delivers a compelling argument for treating hypertension via CBP, with CBP readings taken non invasively via PWA and with CBP targets for the clinician to achieve better outcomes for patients. It really is quite compelling, even if the authors happen to work for Cardiex !
I see this as an important step in delivering a successful commercial outcome for Conneqt Pulse and the clinical portal by helping build credibility and a solid scientific basis for using our patented technology. This, along with the fact we have our CPT code for reimbursement, builds a compelling case for clinicians I would have thought !
You just get the feeling everyone at Cardiex ( & it’s shareholders ) are champing at the bit for Conneqt Pulse FDA clearance, with a whole raft of activities ready to role on the back of that announcement.
Sellers are drying up … how more tightly wound can a stock get!
Add to My Watchlist
What is My Watchlist?
